


Docket No.: 277165US0PCT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313



RE: Application Serial No.: 10/549,502

Applicants: Youcef FEZOUI, et al.

Filing Date: September 14, 2005

For: AMYLIN AGGREGATION INHIBITORS AND USE  
THEREOF

Group Art Unit:

Examiner:

SIR:

Attached hereto for filing are the following papers:

**Notification of Missing Requirements - Attorney/Applicant Copy (2 pp.)****Request for Extension of Time (One Month)****Filing of Declaration Under 37 CFR 1.53(f)****Declaration, Power of Attorney and Petition (Executed, 2 pp.)****Letter Submitting Replacement Drawing Sheet(s)****Drawing Sheet (1)****Preliminary Amendment and Statement (5 pp.)****Substitute Sequence Listing (paper, 6 pp.)****Computer-Readable Sequence Listing (Diskette)**

Our credit card payment form in the amount of \$120.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

A handwritten signature of Norman F. Oblon, consisting of stylized initials and a surname, is written over a horizontal line.

Charles J. Andres Jr., Ph.D.  
Registration No. 57,537

Customer Number

22850

(703) 413-3000 (phone)  
(703) 413-2220 (fax)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/549,502	Youcef Fezoui	277165US0PCT
INTERNATIONAL APPLICATION NO.		
PCT/EP04/50320		
I.A. FILING DATE		PRIORITY DATE
03/17/2004		03/18/2003
<b>CONFIRMATION NO. 7750</b>		
<b>371 FORMALITIES LETTER</b>		
 *OC000000019518035*		

Date Mailed: 07/07/2006

**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 09/14/2005
- Copy of the International Search Report filed on 09/14/2005
- Preliminary Amendments filed on 09/14/2005
- Information Disclosure Statements filed on 12/13/2005
- Request for Immediate Examination filed on 09/14/2005
- Copy of references cited in ISR filed on 09/14/2005
- U.S. Basic National Fees filed on 09/14/2005
- Specification filed on 09/14/2005
- Claims filed on 09/14/2005
- Abstracts filed on 09/14/2005
- Drawings filed on 09/14/2005

RECEIVED: 7/11/06  
 OBLON, SPIVAK, McCLELLAND  
 MAIER & NEUSTADT, P.C.  
**DOCKETING DEPT.**  
 Initials/Date Docketed: MF 7/11/06  
 Type of Resp(s): ECI Sequence Listing  
 Due Date(s): 9/7/06

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.

Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DARRELL C COTTMAN

---

Telephone: (703) 308-9140 EXT 203

**PART 1 - ATTORNEY/APPLICANT COPY**

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/549,502	PCT/EP04/50320	277165US0PCT

---

Docket No. 277165US0PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Youcef FEZOUI, et al.

SERIAL NUMBER: 10/549,502

ATTN: APPLICATION BRANCH

FILING DATE: September 14, 2005

FOR: AMYLIN AGGREGATION INHIBITORS AND USE THEREOF

**FILING OF DECLARATION UNDER 37 CFR 1.53(f)**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Responsive to the notification dated July 7, 2006, and in accordance with the provisions of 37 CFR 1.53(f), Applicants submit herewith a Rule 63 Declaration. The required fee was paid at the time of filing the application.

The Declaration enclosed herewith contains the following information:

Name(s) of Inventor(s)

Title of Invention

Attorney Docket Number


Filing Date

thereby adequately identifying the above-identified application in accordance with 37 CFR 1.63, as set forth in MPEP Section 601.01.

In light of the foregoing, this application is deemed to be in proper condition for examination and such favorable action is earnestly solicited.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

  
Charles J. Andres Jr., Ph.D.  
Registration No. 57,537

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Docket No.: 277165US0PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN RE APPLICATION:** Youcef FEZOUI, et al.

**SERIAL NO.:** 10/549,502

**FILED:** September 14, 2005

**FOR:** AMYLIN AGGREGATION INHIBITORS AND USE THEREOF

**LETTER SUBMITTING REPLACEMENT DRAWING SHEET(S)**

**COMMISSIONER FOR PATENTS**  
Alexandria, VA 22313

**SIR:**

Responsive to the below indicated communication, the following drawing sheets are submitted herewith:

1 Replacement Drawing Sheets       \_\_\_\_\_ New Drawing Sheets

Official Action dated \_\_\_\_\_  
 Notice of Allowance/Issue Fee dated \_\_\_\_\_  
 NOTIFICATION OF MISSING REQUIREMENTS dated JULY 7, 2006

The changes and/or modifications made include the following:

The attached Replacement Drawing sheet for the Fig. 1 has been corrected. The original Fig. 1, filed with the application, contained 5 typographical errors within the Seq. ID numbers. They were originally written as follows: SEQ ID No's. 4, 5, 6, 7 & 8. They have been corrected to correspond with the sequence listing as: SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ. ID NO.8 AND SEQ. ID NO.9. No new matter has been introduced.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Charles J. Andres Jr.,Ph.D.  
Registration No. 57,537

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 06/04)